


## Thalidomide-O-amido-CH<sub>2</sub>-PEG<sub>3</sub>-CH<sub>2</sub>-NH-Boc

<b>Cat. No.:</b>	HY-145177
<b>CAS No.:</b>	1799711-31-1
<b>Molecular Formula:</b>	C <sub>30</sub> H <sub>42</sub> N <sub>4</sub> O <sub>11</sub>
<b>Molecular Weight:</b>	634.67
<b>Target:</b>	E3 Ligase Ligand-Linker Conjugates
<b>Pathway:</b>	PROTAC
<b>Storage:</b>	-20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (157.56 mM; Need ultrasonic)

Concentration	Mass			
	1 mg	5 mg	10 mg	
1 mM	1.5756 mL	7.8781 mL	15.7562 mL	
5 mM	0.3151 mL	1.5756 mL	3.1512 mL	
10 mM	0.1576 mL	0.7878 mL	1.5756 mL	

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Thalidomide-O-amido-CH<sub>2</sub>-PEG<sub>3</sub>-CH<sub>2</sub>-NH-Boc is a synthesized E3 ligase ligand-linker conjugate. Thalidomide-O-amido-CH<sub>2</sub>-PEG<sub>3</sub>-CH<sub>2</sub>-NH-Boc incorporates the Thalidomide based cereblon ligand and a linker. Thalidomide-O-amido-CH<sub>2</sub>-PEG<sub>3</sub>-CH<sub>2</sub>-NH-Boc can be used for the synthesis of PROTAC BET degrader<sup>[1]</sup>. (From patent WO2017180417A1 compound s7).

#### IC<sub>50</sub> & Target

Cereblon

### REFERENCES

[1]. Shaomeng Wang, et al. Bet protein degraders. WO2017180417A1.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA